title: Metabolic effects of anti-angiogenic therapy in tumors.
abstract: Anti-angiogenic therapy has recently been added to the panel of cancer therapeutics, but predictive biomarkers of response are still not available. In animal models, anti-angiogenic therapy causes tumor starvation by increasing hypoxia and impairing nutrients supply. It is thus conceivable that angiogenesis inhibition causes remarkable metabolic perturbations in tumors, although they remain largely uncharted. We review here recent acquisitions about metabolic effects of angiogenesis blockade in tumors and discuss the possibility that some metabolic features of tumor cells - i.e. their dependency from glucose as primary energy substrate - might affect tumor responses to anti-VEGF treatment.
authors.affiliation: Istituto Oncologico Veneto - IRCCS, via Gattamelata, 64 - 35128 Padova, Italy.
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Zulato
authors.forename: Matteo
authors.initials: M
authors.lastname: Curtarello
authors.forename: Giorgia
authors.initials: G
authors.lastname: Nardo
authors.forename: Stefano
authors.initials: S
authors.lastname: Indraccolo
mesh_terms: D000263:Adenylate Kinase / Q000378:metabolism; D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use*; D000068258:Bevacizumab; D015687:Cell Hypoxia; D002986:Clinical Trials as Topic; D004789:Enzyme Activation / Q000187:drug effects; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000263:Adenylate Kinase